Advertisement
Canada markets open in 1 hour 30 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7323
    -0.0000 (-0.01%)
     

  • CRUDE OIL

    84.10
    +0.53 (+0.63%)
     

  • Bitcoin CAD

    87,711.85
    +513.58 (+0.59%)
     

  • CMC Crypto 200

    1,384.51
    -12.02 (-0.86%)
     

  • GOLD FUTURES

    2,355.60
    +13.10 (+0.56%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,736.75
    +169.25 (+0.96%)
     

  • VOLATILITY

    15.61
    +0.24 (+1.56%)
     

  • FTSE

    8,117.05
    +38.19 (+0.47%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6829
    +0.0008 (+0.12%)
     

Wall Street Fundamentals Releases New In-Depth Stock Reports on CLDX, IDIX, IDRA and MNKD

ACCESSWIRE

The biotech industry has continued to thrive in 2014 as the broader markets have struggled to stay in positive territory. The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB - News) and the SPDR S&P Biotech ETF (NYSEARCA:XBI - News) have posted gains of approximately 12.5 percent and 20.8 percent, respectively, year-to-date. Year-to-date gains in the industry have been led by Intercept Pharmaceuticals Inc. (496%), InterMune Inc. (119%) and Furiex Pharmaceuticals Inc. (115%). Here is how some Biotech stocks reacted Monday:

Celldex Therapeutics, Inc. (NASDAQ:CLDX - News) shares traded in the range of $23.44 to $25.22 Monday before settling to close at $24.18, an increase of 4.49 percent. The stock appears to be facing some resistance at the $23.40 and $24.25 levels with some support at $22.17 and $21.51. Shares of Celldex Therapeutics are down approximately 0.10 percent year-to-date.

More information on Celldex Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CLDX

Idenix Pharmaceuticals Inc. (NASDAQ:IDIX - News) shares traded in the range of $7.03 to $7.30 Monday before settling to close at $7.21, an increase of 3.89 percent. The stock appears to be facing some resistance at the $7.06 and $7.48 levels with some support at $6.59 and $5.62. Shares of Idenix Pharmaceuticals are up approximately 20.0 percent year-to-date.

ADVERTISEMENT

More information on Idenix Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/IDIX

Idera Pharmaceuticals Inc. (NASDAQ:IDRA - News) shares traded in the range of $5.73 to $6.10 Monday before settling to close at $6.32, an increase of 6.32 percent. The stock appears to be facing some resistance at the $5.75 and $6.41 levels with some support at $5.53 and $5.28. Shares of Idera Pharmaceuticals are up approximately 30.0 percent year-to-date.

More information on Idera Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/IDRA

MannKind Corporation (NASDAQ:MNKD - News) shares traded in the range of $5.53 to $5.69 Monday before settling to close at $5.58, a decrease of 0.89 percent. The stock appears to be facing some resistance at the $5.68 and $5.83 levels with some support at $5.49 and $5.39. Shares of MannKind are up approximately 7.0 percent year-to-date.

More information on MannKind and access to the free equity report can be found at:
www.WallStreetFundamentals.com/MNKD

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com